These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35775493)

  • 1. Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.
    Güneş M; Karavana SY
    Turk J Pharm Sci; 2022 Jun; 19(3):343-352. PubMed ID: 35775493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
    Rosqvist K; Odin P; Hagell P; Iwarsson S; Nilsson MH; Storch A
    J Parkinsons Dis; 2018; 8(3):409-420. PubMed ID: 30056433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future.
    Ray Chaudhuri K; Qamar MA; Rajah T; Loehrer P; Sauerbier A; Odin P; Jenner P
    NPJ Parkinsons Dis; 2016; 2():16023. PubMed ID: 28725704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.
    Metta V; Batzu L; Leta V; Trivedi D; Powdleska A; Mridula KR; Kukle P; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.
    Tanaka Y; Kato T; Nishida H; Araki H; Murase M; Nagaki M; Moriwaki H; Inuzuka T
    J Neurol; 2009 Dec; 256(12):1972-6. PubMed ID: 19575260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study.
    Larsen JP; Karlsen K; Tandberg E
    Mov Disord; 2000 Sep; 15(5):826-9. PubMed ID: 11009186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular Vesicles in the Treatment of Parkinson's Disease: A Review.
    Yang X; Ma Y; Xie H; Dong S; Rao G; Yang Z; Zhang J; Wu Q
    Curr Med Chem; 2021; 28(31):6375-6394. PubMed ID: 33441061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Update on Medical and Surgical Treatments of Parkinson's Disease.
    Nemade D; Subramanian T; Shivkumar V
    Aging Dis; 2021 Jul; 12(4):1021-1035. PubMed ID: 34221546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the Clinical Features of Parkinson's Disease With Probable Rapid Eye Movement Sleep Behavior Disorder.
    Long K; Wan C; Xiang Y; Liu J; Xu Q; Sun Q; Wang Z; Tian Y; Fang L; Yang Y; Yan X; Tang B; Guo J
    Front Neurol; 2020; 11():979. PubMed ID: 33041969
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study.
    Rizos A; Martinez-Martin P; Odin P; Antonini A; Kessel B; Kozul TK; Todorova A; Douiri A; Martin A; Stocchi F; Dietrichs E; Chaudhuri KR;
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1231-5. PubMed ID: 25269446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
    Kulisevsky J; Bejr-Kasem H; Martinez-Horta S; Horta-Barba A; Pascual-Sedano B; Campolongo A; Marín-Lahoz J; Aracil-Bolaños I; Pérez-Pérez J; Izquierdo-Barrionuevo C; de Fàbregues O; Puente V; Crespo-Cuevas A; Calopa M; Pagonabarraga J
    J Neurol; 2020 Nov; 267(11):3400-3410. PubMed ID: 32607644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
    Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.
    Pahwa R; Aldred J; Gupta N; Terasawa E; Garcia-Horton V; Steffen DR; Kandukuri PL; Chaudhari VS; Jalundhwala YJ; Bao Y; Kukreja P; Isaacson SH
    Neurol Ther; 2022 Jun; 11(2):711-723. PubMed ID: 35192177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.